Supporting prostate cancer research

MindOnLine: A mindfulness program for people with breast, bowel or prostate cancer.

In this study we will run a randomised controlled trial of an online mindfulness program (called MindOnLine) for people living with breast, bowel or prostate cancer. MindOnLine is a 9-week program comprising several components including videos, guided audios, self-reflections and goal setting to help guide mindfulness practice. Participants will be randomly assigned to either the intervention group with immediate access to MindOnLine, or a waitlist group who will receive access to MindOnLine after the last follow up point. The aims of this study are to determine the effect of MindOnLine on fear of cancer recurrence, anxiety and depression. Participants will be asked to complete questionaries at baseline, 9 weeks and 9 months. The primary outcome of this study will be a change in fear of cancer recurrence at 9-weeks. An economic analysis will be conducted to inform the cost-effectiveness of the program. This study focuses on breast, bowel and prostate cancer as three of the most common cancers among men and/or women in Australia. Findings will be used to describe the effectiveness in improving wellbeing outcomes of people living with cancer.

After this randomised controlled trial, the MindOnLine program will be rolled out across Australia with partner organisations such as the Department of Health and Human Services, PCFA and Breast Cancer Network of Australia. This program will be freely available to all men living with prostate cancer. Findings will be disseminated to the wider research community through presentations at national and international conferences and manuscripts will be submitted to peer reviewed journals for publication.

Fear of cancer recurrence is a highly prevalent and persistent condition that can result in significant levels of anxiety and depression across the disease trajectory. There is an urgent need to address this issue and early psychosocial support is critical to prevent this problem from becoming a chronic condition. Our recent work into early psychosocial support indicates it may be possible to significantly reduce this level of suffering through a mindfulness program. Mindfulness is a state of mind in which one pays attention to the present experience in a nonjudgmental, curious, accepting way. It has been associated with substantially improved mental health outcomes and management of the emotional consequences of cancer. Using an iterative process MindOnLine has been developed and pilot tested among people living with melanoma and showed a significant reduction in fear of cancer recurrence. Working with our partners, including sector leaders in Government, health services, consumer advocacy and community partner organisations, we are conducting a randomised controlled trial of an updated version of the program (called MindOnLine) across three different cancer streams – breast, prostate and colorectal cancer – to determine the effectiveness, cost-effectiveness and sustainability of this innovative intervention.

In this study we will run a randomised controlled trial of an online mindfulness program (called MindOnLine) for people living with breast, bowel or prostate cancer. MindOnLine is a 9-week program comprising several components including videos, guided audios, self-reflections and goal setting to help guide mindfulness practise. Participants will be randomly assigned to either the intervention group with immediate access to MindOnLine, or a waitlist group who will receive access to MindOnLine after the last follow up point. Participants who are allocated to receive MindOnLine are encouraged to watch short videos to learn about mindfulness once a week and to practice mindfulness each day. To measure the impact of MindOnLine on wellbeing outcomes, participants will be asked to complete questionaries at baseline, 9 weeks and 9 months. Men have said about the program in the past: “I found the use of breathing as an “anchor” quite profound, yet so simple.” “I particularly like the video that explained why we see things the way we do. This really put everything into perspective for me.” For more information or to register visit: https://mindonline.org.au

To be eligible you must be over the age of 18, speak and read English, have access to the Internet and have finished treatment within the last five years. Men with local, locally advanced cancers, those under active surveillance (watch and wait) and men receiving hormonal therapy (ADT) are eligible.

Join us today!

Pathfinder is a unique prostate cancer research register that enables prostate cancer survivors to participate in research for a brighter future with their loved ones.

It will enable researchers to save valuable time and money recruiting participants for their projects, so that they can spend more time delivering health benefits to those in need. Click the button to the right to register!